Supplementary Figure S1 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Key Points

• Clonal hematopoiesis and inflammation significantly predict hematologic toxicity in patients after CAR-T therapy, influencing treatment outcomes.
• Findings indicate that higher levels of both factors were associated with decreased overall survival and progression-free survival rates.
• Analysis of survival rates was based on myeloid recovery status at 30 days post CAR-T infusion, utilizing hazard ratios for statistical evaluation.
• This study emphasizes the importance of monitoring clonal hematopoiesis and inflammation to improve patient management strategies in CAR-T therapy.